Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9578 posts found.

Trial data shows promise for Lilly/MSD combo regimen in lung cancer

June 6, 2016 Research and Development, Sales and Marketing MSD, Merck, collaboration, immuno-oncology, lilly, lung cancer, non-small cell, parternship

Eli Lilly (NYSE: LLY) has presented data at the American Society of Clinical Oncology (ASCO) annual congress showcasing its collaborations …
News
opdivo_1

Bristol-Myers Squibb presents Opdivo data at ASCO

June 6, 2016 Research and Development, Sales and Marketing ASCO, Bristol-Myers Squibb, opdivo

Bristol-Myers Squibb (NYSE: BMY) has presented a wide range of results on Opdivo (nivolumab) in a range of oncology indications …
News
janssen_latest_logo_on_sign_closer

Janssen says combination Phase III study for immunotherapy Darzalex for multiple myeloma shows significant PFS

June 6, 2016 Research and Development, Sales and Marketing ASCO, Drig Trial, Janssen, multiple myeloma

Janssen said combination late stage trials for its immunotherapy drug to treat multiple myeloma showed 61% progression-free survival.  The company …
News

Roche says Phase III trials for giant cell arteritis drug met primary endpoint

June 6, 2016 Research and Development, Sales and Marketing Roche, arthritis, drug trial

Cancer drugmaker Roche (SIX: ROG) said late stage trials for its drug to treat giant cell arteritis (GCA) met its …
News
sample

Sanofi and Regeneron combo shows superiority in late-stage atopic dermatitis trials

June 6, 2016 Research and Development, Sales and Marketing Dupilumab, Regeneron, Sanofi, atopic dermatitis, late stage trials

Sanofi (NYSE: SNY) and Regeneron (NASDAQ: REGN) have announced positive results from a Phase III trial evaluating dupilumab in patients …
News
novo_flag

Novo Nordisk presents positive long-term results for Saxenda

June 3, 2016 Medical Communications, Research and Development Novo Nordisk, cardiometabolic risk factors, liraglutide, saxenda, weight loss

Novo Nordisk has presented analysis covering three years of a late-stage trial for Saxenda (liarglutide 3mg) , which showed the …
News
shire_image_4

Shire completes Baxalta takeover

June 3, 2016 Medical Communications, Research and Development, Sales and Marketing Baxalta, Shire, deal, merger and acquisition, revenue, sales

UK drugmaker Shire (LSE: SHP) on Friday announced the completion of merger with rare disease specialist Baxalta (NYSE: BXLT).  The …
News

Bayer, Orion to start Phase III trials for prostate cancer drug

June 3, 2016 Medical Communications, Research and Development, Sales and Marketing Bayer, drug trial, orion, prostate cancer, research

German pharma and crop sciences giant Bayer (ETR: BAYN) and Orion Corp (Nasdaq Helsinki: ORNAV) have agreed to start a Phase …
News

New FDA expanded access guidelines spell trouble for Sarepta

June 2, 2016 Medical Communications, Research and Development, Sales and Marketing Duchenne Muscular Dystrophy, Eteplirsen, FDA, compassionate grounds, sarepta

New guidelines intended to streamline the process of expanded access to medicines by the US Food and Drug Administration (FDA) …
News
biogen_austria_238

Biogen Alzheimer’s treatment accepted into EMA’s PRIME scheme

June 2, 2016 Research and Development, Sales and Marketing Alzheimer's, Biogen, EMA, PRIME, accelerated approval

Biogen (NASDAQ: BIIB) has announced that the European Medicines Agency (EMA) has accepted its investigational treatment for Alzheimer’s disease, aducanumab, …
News
cancer_cells

Global oncology market to reach $150 billion by 2020, says IMS Health

June 2, 2016 Research and Development IMS Health, annual global growth, cancer drugs, oncology

Global sales of oncology drugs rose to $107 billion in 2015, according to a new IMS Health report, with growth …
News

Novartis’ Afinitor gets EU approval to treat cancerous gastrointestinal or lung tumors

June 2, 2016 Research and Development, Sales and Marketing Afinitor, Cancer, European Commission, Novartis, regulation

Swiss drugmaker Novartis (VTX: NOVN) on Thursday said the European Commission has approved its Afinitor (everolimus) to treat cancerous gastrointestinal …
News
clinical_trial_4

Phase III trials to start in Novartis/Genmab multiple sclerosis collaboration

June 2, 2016 Research and Development Arzerra, Genmab, Novartis, multiple sclerosis, ofatumumab, phase III

Genmab (NASDAQ: GEN) has announced that its collaboration partner, Novartis, is set to initiate Phase III trials for ofatumumab in …
News
janssen_latest_logo_on_sign_closer

Janssen says its Trevicta gets European regulatory approval as maintenance therapy for Schizophrenia

June 2, 2016 Medical Communications, Research and Development European Commission, Janssen, Trevicta, schizophrenia

Janssen said the European Commission has approved its Trevicta (paliperidone palmitate, a 3‑monthly injection) as maintenance treatment of schizophrenia.  Trevicta …
News

Nice rejects Janssen’s Imbruvica in draft guidance

June 1, 2016 Medical Communications, Research and Development

The UK regulators have not recommended Janssen’s leukaemia drug Imbruvica (ibrutinib) to treat in draft guidance. The National Institute for …
News
The Gateway to Local Adoption Series

Latest content

Just – Evotec given Gates Foundation grant to increase global biotherapeutics access

January 8, 2026

Johnson & Johnson submits robotic surgical system for De Novo classification

January 8, 2026

EA Pharma announces phase 3 trial for new schizophrenia treatment in Japan

January 7, 2026

Eleva appoints Erich Rajkovic as Chief Business Officer

January 7, 2026

MedPharm announces US FDA inspection of North Carolina manufacturing facility

January 6, 2026